1. Home
  2. BNTC vs GSRT Comparison

BNTC vs GSRT Comparison

Compare BNTC & GSRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • GSRT
  • Stock Information
  • Founded
  • BNTC 1995
  • GSRT 2023
  • Country
  • BNTC United States
  • GSRT United States
  • Employees
  • BNTC N/A
  • GSRT N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • GSRT
  • Sector
  • BNTC Health Care
  • GSRT
  • Exchange
  • BNTC Nasdaq
  • GSRT Nasdaq
  • Market Cap
  • BNTC 365.1M
  • GSRT 303.7M
  • IPO Year
  • BNTC N/A
  • GSRT 2024
  • Fundamental
  • Price
  • BNTC $13.90
  • GSRT $11.89
  • Analyst Decision
  • BNTC Strong Buy
  • GSRT Strong Buy
  • Analyst Count
  • BNTC 5
  • GSRT 2
  • Target Price
  • BNTC $24.80
  • GSRT $19.50
  • AVG Volume (30 Days)
  • BNTC 40.3K
  • GSRT 2.6M
  • Earning Date
  • BNTC 11-13-2025
  • GSRT 01-01-0001
  • Dividend Yield
  • BNTC N/A
  • GSRT N/A
  • EPS Growth
  • BNTC N/A
  • GSRT N/A
  • EPS
  • BNTC N/A
  • GSRT 0.19
  • Revenue
  • BNTC N/A
  • GSRT N/A
  • Revenue This Year
  • BNTC N/A
  • GSRT N/A
  • Revenue Next Year
  • BNTC N/A
  • GSRT N/A
  • P/E Ratio
  • BNTC N/A
  • GSRT $62.01
  • Revenue Growth
  • BNTC N/A
  • GSRT N/A
  • 52 Week Low
  • BNTC $9.09
  • GSRT $8.82
  • 52 Week High
  • BNTC $17.15
  • GSRT $14.64
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 54.74
  • GSRT 70.65
  • Support Level
  • BNTC $13.49
  • GSRT $8.82
  • Resistance Level
  • BNTC $14.01
  • GSRT $14.64
  • Average True Range (ATR)
  • BNTC 0.54
  • GSRT 0.75
  • MACD
  • BNTC -0.04
  • GSRT 0.16
  • Stochastic Oscillator
  • BNTC 64.70
  • GSRT 53.61

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

About GSRT GSR III Acquisition Corp. Ordinary Shares

GSR III Acquisition Corp is a blank check company.

Share on Social Networks: